Neoadjuvant Immunochemotherapy for Locally Advanced Oral Squamous Cell Carcinoma: A Case Report

ABSTRACT The basic treatment principle for patients with advanced oral cancer is holistic therapy based on surgery. However, the radical resection may cause functional disorders in patients and there is also a risk of local recurrence and distant metastasis. Neoadjuvant immunochemotherapy can promote complete resection and improve treatment outcomes for patients with advanced oral cancer by reducing tumor burden and clearing microscopic metastases. Here, we describe the case of a 63‐year‐old female patient who presented in early 2025 with oral squamous cell carcinoma (OSCC) of the left buccal mucosa. The patient was treated with two cycles of neoadjuvant immunochemotherapy with the specific regimen of tislelizumab, cisplatin, and albumin‐bound paclitaxel, followed by surgical treatment after the neoadjuvant therapy. The patient's clinical response was assessed as partial response with good pathological response. This case presented the application of neoadjuvant immunochemotherapy in patients with locally advanced OSCC. In terms of short‐term efficacy, the neoadjuvant immunochemotherapy regimen comprising tislelizumab, cisplatin, and albumin‐bound paclitaxel helped patients achieve tumor shrinkage and improve surgical outcomes.